REPERFUSION TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Global Reperfusion Treatment Market– Drivers

Increasing research and development activities related to perfusion treatment

Increasing research and development in the field of perfusion treatment is expected to drive the global reperfusion treatment market growth over the forecast period. For instance, on June 27, 2023, Society of Nuclear Medicine and Molecular Imaging, a journal published an article explaining how a novel PET perfusion radiotracer, 18F-flurpiridaz, can diagnose coronary artery disease (CAD) in obese patients with a higher sensitivity and specificity as compared to 99mTc-SPECT myocardial perfusion imaging (MPI). 18F-flurpiridaz PET MPI performed as well in patients with and without obesity while producing images at a lower radiation dosage than 99mTc-SPECT MPI. Obese people frequently suffer from illnesses like diabetes, high cholesterol, and high blood pressure thatincrease their risk of developing CAD. Imaging obese patients for CAD is crucial due to these risk factors.

Global Reperfusion Treatment Market: Restraints

Side effects and risks associated with perfusion treatment

The side effects and risks associated with perfusion treatment can hamper the global reperfusion treatment market growth. For instance, on January 3, 2020, according to the Peter MacCallum Cancer Centre, a facility for cancer research, education, and treatment Isolated Limb Perfusion (ILP) is a surgical technique, thus it has risks and side effects. The majority of these risks and side effects are minimal and easily tolerated. Patients will experience some pain, swelling, and redness in the limb following ILP. This lasts six to eight weeks, or two months. In most cases, simple painkillers like paracetamol are used for treatments. After ILP, patients might experience more severe symptoms that necessitate a longer hospital stay. Typically, patients go away on their own without any special care. Although possible, extremely severe side effects are very uncommon.

To counterbalance this restraint, more research and development should be done to avoid side effects and risks for the betterment of patients.